Retina Clinical Trials

135 recruitingLast updated: July 25, 2026

There are 135 actively recruiting retina clinical trials across 35 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, Shanghai, Shanghai Municipality, China, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Retina Trials at a Glance

135 actively recruiting trials for retina are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Not Applicable with 45 trials, with the heaviest enrollment activity in Houston, Shanghai, and Ann Arbor. Lead sponsors running retina studies include National Eye Institute (NEI), Duke University, and Peking Union Medical College Hospital.

Treatments under study

About Retina Clinical Trials

Looking for clinical trials for Retina? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Retina trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Retina clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 135 trials

Recruiting

Rod and Cone Mediated Function in Retinal Disease

Stargardt's DiseaseRetinal DegenerationRetinitis Pigmentosa
National Eye Institute (NEI)500 enrolled1 locationNCT02617966
Recruiting
Not Applicable

Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

Epiretinal Membrane
Jaeb Center for Health Research400 enrolled48 locationsNCT05145491
Recruiting

DISCOVER Study: Microscope-integrated Intraoperative OCT Study

Retinal diseasesEpiretinal MembraneRetinal Detachment+2 more
The Cleveland Clinic3,000 enrolled1 locationNCT02423213
Recruiting
Phase 3

Efficacy and Safety Evaluation of SMO1 in Patients With Retinal Vein Occlusive Macular Edema

Retinal Vein Occlusion With Macular Edema
SANGMYUNG innovation312 enrolled1 locationNCT07708142
Recruiting

Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene

Retinal DiseaseGenotype
National Eye Institute (NEI)320 enrolled1 locationNCT01145196
Recruiting

Mapping of the Developmental Atlas of the Visual System and Research on Embryonic Neurogenesis Phenomena

Embryonic DevelopmentRetinal AnomaliesNeural Development
Sheng Liu200 enrolled1 locationNCT07688538
Recruiting
Phase 1Phase 2

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Retinitis pigmentosa (RP)Retinal DegenerationPrimary Photoreceptor Disease+6 more
BlueRock Therapeutics54 enrolled5 locationsNCT06789445
Recruiting
Not Applicable

(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000

Dry Age-Related Macular DegenerationEpiretinal MembraneMacular Abnormalities+7 more
Carl Zeiss Meditec-Dublin CoCe400 enrolled6 locationsNCT07680244
Recruiting

National Eye Institute Biorepository for Retinal Diseases

Age-Related Macular DegenerationDiabetic RetinopathyRetinal Disease+2 more
National Eye Institute (NEI)650 enrolled1 locationNCT01496625
Recruiting
Phase 3

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Sensation DisordersLeber Congenital AmaurosisRetinal Disease+7 more
Laboratoires Thea32 enrolled17 locationsNCT06891443
Recruiting

Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants

Retinitis PigmentosaInherited Retinal Degeneration
Jaeb Center for Health Research1,500 enrolled36 locationsNCT05589714
Recruiting
Not Applicable

Stem Cell Ophthalmology Treatment Study II

Age-Related Macular DegenerationRetinitis PigmentosaMacular Degeneration+15 more
MD Stem Cells500 enrolled4 locationsNCT03011541
Recruiting
Phase 4

Dropless Pars Plana Vitrectomy Study

rhegmatogenous retinal detachment
Massachusetts Eye and Ear Infirmary168 enrolled1 locationNCT05331664
Recruiting
Not Applicable

The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services

Cardiac conditionsCancerConnective Tissue Diseases+4 more
Unity Health Toronto170 enrolled3 locationsNCT06455384
Recruiting

Cell Collection to Study Eye Diseases

Retinal DegenerationRetinitis PigmentosaRetinal Disease+1 more
National Eye Institute (NEI)930 enrolled1 locationNCT01432847
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting
Phase 2

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

Neovascular Age-Related Macular Degeneration (NVAMD)Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.160 enrolled49 locationsNCT07205887
Recruiting
Phase 2

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

deaf-blindRetinitis pigmentosa (RP)Retinal Disease+4 more
Laboratoires Thea81 enrolled28 locationsNCT06627179
Recruiting
Early Phase 1

Safety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy

Inherited Retinal DystrophyInherited Retinal Disease
Peking Union Medical College Hospital6 enrolled1 locationNCT07656753
Recruiting
Not Applicable

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Diabetic RetinopathyHypertension,EssentialRetinal Vein Occlusion+1 more
Johns Hopkins University1,050 enrolled1 locationNCT04505618